Aggrenox

AssetAlso called Asasantin, dipyridamole, acetylsalicylic acid, modified-release dipyridamole

Fixed combination of aspirin and dipyridamole acting as antiplatelet agents

Stage
Approved, not sold in the US
Modality
Small molecule
Target
SLC29A1
3
Indications
9
Trials
1
Developer

Approved by the FDA on Nov 22, 1999 (NDA020884). Not sold in the US: Drugs@FDA marks every US product that holds it discontinued. FDA

Indications

3

In the full profile

  • Target and mechanism25
  • Owner and partners3
  • Trials9
  • Evidence for its targets8
  • Competitors12
  • Aging relevance1
  • Signals12

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets